Cai G, Michigami T, Yamamoto T, Yasui N, Satomura K, Yamagata M, Shima M, Nakajima S, Mushiake S, Okada S, Ozono K
Department of Environmental Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Japan.
J Clin Endocrinol Metab. 1998 Nov;83(11):3936-42. doi: 10.1210/jcem.83.11.5267.
Hypophosphatasia is associated with a defect of the tissue-nonspecific alkaline phosphatase (TNSALP) gene. The onset and clinical severity are usually correlated in hypophosphatasia; patients with perinatal hypophosphatasia die approximately at the time of birth. In contrast, we describe a male neonatal patient with hypophosphatasia who had no respiratory problems and survived. He was compound heterozygous for the conversion of Phe to Leu at codon 310 (F310L) and the deletion of a nucleotide T at 1735 (delT1735), causing the frame shift with the result of the addition of 80 amino acids at the C-terminal of the protein. Because the C-terminal portion of TNSALP is known to be important for TNSALP to bind to the plasma membrane, the localization of wild-type and mutated TNSALP proteins was analyzed using green fluorescent protein chimeras. The expression vectors containing the complementary DNA of fusion proteins consisting of signal peptide, green fluorescent protein, and wild-type or mutated TNSALP, caused by delT1735 or F310L mutation, were introduced transiently or stably in Saos-2 cells. The delT1735 mutant failed to localize at the cell surface membrane, whereas the wild-type and the F310L mutants were located in the plasma membrane and cytoplasm. The assay for enzymatic activity of TNSALP revealed that the delT1735 mutant lost the activity and that the F310L mutant exhibited an enzymatic activity level that was 72% of the normal level. The F310L mutation was also detected in another neonatal patient with relatively mild (nonlethal) hypophosphatasia (reported in J Clin Endocrinol Metab, 81:4458-4461, 1996), suggesting that residual ALP activity of the F310L mutant contributes to the less severe phenotype. The patient is unique, with respect to a discrepancy between onset and clinical severity in hypophosphatasia.
低磷酸酯酶症与组织非特异性碱性磷酸酶(TNSALP)基因缺陷有关。低磷酸酯酶症的发病和临床严重程度通常相关;围产期低磷酸酯酶症患者大约在出生时死亡。相比之下,我们描述了一名患有低磷酸酯酶症的男性新生儿患者,他没有呼吸问题并存活了下来。他在密码子310处发生了苯丙氨酸(Phe)到亮氨酸(Leu)的转换(F310L)以及1735位核苷酸T的缺失(delT1735),为复合杂合子,这导致了移码,结果在蛋白质的C末端添加了80个氨基酸。由于已知TNSALP的C末端部分对于TNSALP结合质膜很重要,因此使用绿色荧光蛋白嵌合体分析了野生型和突变型TNSALP蛋白的定位。将含有由信号肽、绿色荧光蛋白以及由delT1735或F310L突变导致的野生型或突变型TNSALP组成的融合蛋白互补DNA的表达载体瞬时或稳定地导入Saos-2细胞。delT1735突变体未能定位在细胞表面膜,而野生型和F310L突变体位于质膜和细胞质中。TNSALP的酶活性测定表明,delT1735突变体失去了活性,而F310L突变体表现出的酶活性水平为正常水平的72%。在另一名患有相对轻度(非致死性)低磷酸酯酶症的新生儿患者中也检测到了F310L突变(发表于《临床内分泌与代谢杂志》,81:4458 - 4461, 1996),这表明F310L突变体的残余碱性磷酸酶(ALP)活性导致了较轻的表型。就低磷酸酯酶症的发病与临床严重程度之间的差异而言,该患者是独特的。